Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TMT101 in advanced pancreatic cancer or NSCLC
NCT06861543Phase 1Recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Mar 2025
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TMT101 in pancreatic cancer (PC) and non-small cell lung cancer (NSCLC), sponsored by Peking Union Medical College Hospital. Primary endpoints: Dose-Limiting Toxicities at 21 days, Treatment-Emergent Adverse Events at 2 years and 4 more. Started Mar 2025; status: recruiting.
02
Drugs
TMT101
03
Conditions
pancreatic cancer (PC)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06861543.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06861543.